Arylamine based cathepsin K inhibitors: Investigating P3 heterocyclic substituents

Bioorganic and Medicinal Chemistry

Volumn 14, Issue 20, 2006, Pages 6807-6819

  Shinozuka, Tsuyoshi ^a   Shimada, Kousei ^a   Matsui, Satoshi ^a   Yamane, Takahiro ^a   Ama, Mayumi ^a   Fukuda, Takeshi ^a   Taki, Motohiko ^a   Takeda, Yuko ^a   Otsuka, Eri ^a   Yamato, Michiko ^a   Naito, Satoru ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Cathepsin K; Heterocyclic substituent; Inhibitor; SAR study

Indexed keywords

1 (BIPHENYL 3 YLAMINO) N [2 [(4 METHOXYPHENYL)AMINO]ETHYL] CYCLOHEXANECARBOXAMIDE; [4 [[2 [(N BIPHENYL 3 YL LEUCYL)AMINO]BUTYL]AMINO]PHENOXY]ACETIC ACID 2 HYDROCHLORIDE; [4 [[2 [[N (2 OXO 6 PHENYL 2H PYRAN 4 YL)LEUCYL]AMINO]BUTYL]AMINO]PHENOXY] ACETIC ACID 2 HYDROCHLORIDE; [4 [[2 [[N (5 PHENYLISOXAZOL 3 YL)LEUCYL]AMINO]BUTYL]AMINO]PHENOXY]ACETIC ACID 2 HYDROCHLORIDE; [4 [[2 [[N (MORPHOLIN 4 YLCARBONYL)LEUCYL]AMINO]BUTYL]AMINO]PHENOXY]ACETIC ACID 2 HYDROCHLORIDE; AROMATIC AMINE; CATHEPSIN K INHIBITOR; N 1 [1 [[(4 METHOXYPHENYL)AMINO]METHYL]PROPYL] N 2 (2 OXO 6 PHENYL 2H PYRAN 4 YL)LEUCINAMIDE; N 1 [1 [[(4 METHOXYPHENYL)AMINO]METHYL]PROPYL] N 2 (5 PHENYLISOXAZOL 3 YL)LEUCINAMIDE; N 1 [1 [[(4 METHOXYPHENYL)AMINO]METHYL]PROPYL] N 2 (MORPHOLIN 4 YLCARBONYL)LEUCINAMIDE; N 2 1,1 BIPHENYL 3 YL N 1 1 [[[(4 METHOXYPHENYL)AMINO]METHYL]PROPYL] LEUCINAMIDE; N 2 BIPHENYL 3 YL N 1 [[(4 METHOXYPHENYL)AMINO]METHYL]LEUCINAMIDE; N [1 [[[4 (BENZYLOXY)PHENYL]AMINO]METHYL]PROPYL] N 2 (2 OXO 6 PHENYL 2H PYRAN 4 YL)LEUCINAMIDE; N [1 [[[4 (BENZYLOXY)PHENYL]AMINO]METHYL]PROPYL] N 2 (5 PHENYLISOXAZOL 3 YL)LEUCINAMIDE; N [1 [[[4 (BENZYLOXY)PHENYL]AMINO]METHYL]PROPYL] N 2 (MORPHOLIN 4 YLCARBONYL)LEUCINAMIDE; N [1 [[[4 (BENZYLOXY)PHENYL]AMINO]METHYL]PROPYL] N 2 BIPHENYL 3 YL LEUCINAMIDE; N [2 [(4 METHOXYPHENYL)AMINO]ETHYL] 1 (1 NAPHTHYLAMINO) CYCLOHEXANECARBOXAMIDE; N [2 [(4 METHOXYPHENYL)AMINO]ETHYL] 1 [(2 OXO 2H CHROMEN 4 YL)AMINO]CYCLOHEXANECARBOXAMIDE; N [2 [(4 METHOXYPHENYL)AMINO]ETHYL] 1 [(2 OXO 6 PHENYL 2H PYRAN 4 YL)AMINO]CYCLOHEXANECARBOXAMIDE; N [2 [(4 METHOXYPHENYL)AMINO]ETHYL] 1 [(3 PYRIDIN 2 YLPHENYL)AMINO] CYCLOHEXANECARBOXAMIDE; N [2 [(4 METHOXYPHENYL)AMINO]ETHYL] 1 [(3 PYRIDIN 3 YLPHENYL)AMINO] CYCLOHEXANECARBOXAMIDE; N [2 [(4 METHOXYPHENYL)AMINO]ETHYL] 1 [(3 PYRIDIN 4 YLPHENYL)AMINO] CYCLOHEXANECARBOXAMIDE; N [2 [(4 METHOXYPHENYL)AMINO]ETHYL] 1 [(4 PHENYLPYRIDIN 2 YL)AMINO]CYCLOHEXANECARBOXAMIDE; N [2 [(4 METHOXYPHENYL)AMINO]ETHYL] 1 [(6 PHENYLPYRIDIN 2 YL)AMINO]CYCLOHEXANECARBOXAMIDE; N [2 [(4 METHOXYPHENYL)AMINO]ETHYL] N 2 (2 OXO 6 PHENYL 2H PYRAN 4 YL)LEUCINAMIDE; N [2 [(4 METHOXYPHENYL)AMINO]ETHYL] N 2 (5 PHENYL 1H PYRAZOL 3 YL)LEUCINAMIDE; N [2 [(4 METHOXYPHENYL)AMINO]ETHYL] N 2 (5 PHENYLISOXAZOL 3 YL)LEUCINAMIDE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFECT; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; IC 50; LIPOPHILICITY; NONHUMAN; RAT; REACTION ANALYSIS;

AMINES; CATHEPSIN B; CATHEPSIN K; CATHEPSIN L; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; ENZYME ACTIVATION; ENZYME INHIBITORS; HETEROCYCLIC COMPOUNDS; HUMANS; MOLECULAR CONFORMATION; RECOMBINANT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33748095763     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.06.031     Document Type: Article

References (22)

1. For the crystal structure of cathepsin K, see:. LaLonde J.M., Zhao B., Janson C.A., D'Alessio K.J., McQueney M.S., Orsini M.J., Debouck C.M., and Smith W.W. Biochemistry 38 (1999) 862
2. Shinozuka T., Shimada K., Matsui S., Yamane T., Ama M., Fukuda T., Taki M., and Naito S. Bioorg. Med. Chem. Lett. 16 (2006) 1502
3. Altmann E., Renaud J., Green J., Farley D., Cutting B., and Jahnke W. J. Med. Chem. 45 (2002) 2352
4. Altmann E., Green J., and Tintelnot-Blomley M. Bioorg. Med. Chem. Lett. 13 (2003) 1997
5. Kim T.-S., Hague A.B., Lee T.I., Lian B., Tegley C.M., Wang X., Burgess T.L., Qian Y.-X., Ross S., Tagari P., Lin C.-H., Mayeda C., Dao J., Jordan S., Mohr C., Cheetham J., Viswanadhan V., and Tasker A.S. Bioorg. Med. Chem. Lett. 14 (2004) 87
6. A moderate lipophilicity is preferred for obtaining a good pharmacokinetics, see:. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Delivery Rev. 23 (1997) 3 and references cited therein
7. Miyaura N., and Suzuki A. Chem. Rev. 95 (1995) 2457
8. Ma D., Zhang Y., Yao J., Wu S., and Tao F. J. Am. Chem. Soc. 120 (1998) 12459
9. Fourneau J.-P., and de Lestrange M.Y. Bull. Soc. Chim. Fr. (1947) 827
10. Oh C., Yi I., and Park K.P. J. Heterocycl. Chem. 31 (1994) 841
11. Webber R.K., Metz S., Moore W.M., Connor J.R., Currie M.G., Fok K.F., Hagen T.J., Hansen Jr. D.W., Jerome G.M., Manning P.T., Pitzele B.S., Toth M.V., Trivedi M., Zupec M.E., and Tjoeng F.S. J. Med. Chem. 41 (1998) 96
12. Cihangir T., and Okan T. Synth. Commun. 19 (1989) 2453
13. Fukada N., and Yuzawa M. Bull. Chem. Soc. Jpn. 64 (1991) 3727
14. Mitsunobu O. Synthesis (1981) 1
15. Caputo R., Cassano E., Longobardo L., and Palumbo G. Tetrahedron 51 (1995) 12337
16. Burmistrov K.S., Burmistrov S.I., and Malinovskii M.S. Chem. Heterocycl. Compd. (Engl. Transl.) 13 (1977) 1201
17. Fukuyama T., Cheung M., and Kan T. Synlett (1999) 1301
18. Purified procathepsin K is efficiently activated at lower pH, such as pH 4.0. In addition, the activity of mature cathepsin K at pH 3.8 was around 40% when compared at pH 6.0 using Cbz-Phe-Arg-AMC as a substrate. Therefore, the assays were carried out against recombinant human cathepsin K at pH 3.8. See:. Brömme D., Okamoto K., Wang B.B., and Biroc S. J. Biol. Chem. 271 (1996) 2126
19. Malamas M.S., Sredy J., Moxham C., Katz A., Xu W., McDevitt R., Adebayo F.O., Sawicki D.R., Seestaller L., Sullivan D., and Taylor J.R. J. Med. Chem. 43 (2000) 1293
20. Duan J.J.-W., Lu Z., Xue C.-B., He X., Seng J.L., Roderick J.J., Wasserman Z.R., Liu R.-Q., Covington M.B., Magolda R.L., Newton R.C., Trzasko J.M., and Decicco C.P. Bioorg. Med. Chem. Lett. 13 (2003) 2035
21. Ward Y.D., Thomson D.S., Fry L.L., Cywin C.L., Morwick T., Emmanuel M.J., Zindell R., McNeil D., Bekkali Y., Giradot M., Hrapchak M., DeTuri M., Crane K., White D., Pav S., Wang Y., Hao M.-H., Grygon C.A., Labadia M.E., Freeman D.M., Davidson W., Hopkins J.L., Brown M.L., and Spero D.M. J. Med. Chem. 45 (2002) 5471
22. Huang L., Lee A., and Ellman J.A. J. Med. Chem. 45 (2002) 676